BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Tsai MJ, Hung JY, Lee MH, Kuo CY, Tsai YC, Tsai YM, Liu TC, Yang CJ, Huang MS, Chong IW. Better Progression-Free Survival in Elderly Patients with Stage IV Lung Adenocarcinoma Harboring Uncommon Epidermal Growth Factor Receptor Mutations Treated with the First-line Tyrosine Kinase Inhibitors. Cancers (Basel). 2018;10. [PMID: 30428509 DOI: 10.3390/cancers10110434] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.8] [Reference Citation Analysis]
Number Citing Articles
1 Chen YJ, Roumeliotis TI, Chang YH, Chen CT, Han CL, Lin MH, Chen HW, Chang GC, Chang YL, Wu CT, Lin MW, Hsieh MS, Wang YT, Chen YR, Jonassen I, Ghavidel FZ, Lin ZS, Lin KT, Chen CW, Sheu PY, Hung CT, Huang KC, Yang HC, Lin PY, Yen TC, Lin YW, Wang JH, Raghav L, Lin CY, Chen YS, Wu PS, Lai CT, Weng SH, Su KY, Chang WH, Tsai PY, Robles AI, Rodriguez H, Hsiao YJ, Chang WH, Sung TY, Chen JS, Yu SL, Choudhary JS, Chen HY, Yang PC, Chen YJ. Proteogenomics of Non-smoking Lung Cancer in East Asia Delineates Molecular Signatures of Pathogenesis and Progression. Cell 2020;182:226-244.e17. [PMID: 32649875 DOI: 10.1016/j.cell.2020.06.012] [Cited by in Crossref: 41] [Cited by in F6Publishing: 37] [Article Influence: 41.0] [Reference Citation Analysis]
2 Kuo CY, Lee MH, Tsai MJ, Yang CJ, Hung JY, Chong IW. The Factors Predicting Concordant Epidermal Growth Factor Receptor (EGFR) Mutation Detected in Liquid/Tissue Biopsy and the Related Clinical Outcomes in Patients of Advanced Lung Adenocarcinoma with EGFR Mutations. J Clin Med 2019;8:E1758. [PMID: 31652678 DOI: 10.3390/jcm8111758] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
3 Chen YC, Tsai MJ, Lee MH, Kuo CY, Shen MC, Tsai YM, Chen HC, Hung JY, Huang MS, Chong IW, Yang CJ. Lower starting dose of afatinib for the treatment of metastatic lung adenocarcinoma harboring exon 21 and exon 19 mutations. BMC Cancer 2021;21:495. [PMID: 33941115 DOI: 10.1186/s12885-021-08235-3] [Reference Citation Analysis]
4 John T, Taylor A, Wang H, Eichinger C, Freeman C, Ahn MJ. Uncommon EGFR mutations in non-small-cell lung cancer: A systematic literature review of prevalence and clinical outcomes. Cancer Epidemiol 2021;76:102080. [PMID: 34922050 DOI: 10.1016/j.canep.2021.102080] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
5 Russo A, Franchina T, Ricciardi G, Battaglia A, Picciotto M, Adamo V. Heterogeneous Responses to Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitors (TKIs) in Patients with Uncommon EGFR Mutations: New Insights and Future Perspectives in this Complex Clinical Scenario. Int J Mol Sci 2019;20:E1431. [PMID: 30901844 DOI: 10.3390/ijms20061431] [Cited by in Crossref: 22] [Cited by in F6Publishing: 27] [Article Influence: 7.3] [Reference Citation Analysis]
6 He SY, Lin QF, Chen J, Yu GP, Zhang JL, Shen D. Efficacy of afatinib in a patient with rare EGFR (G724S/R776H) mutations and amplification in lung adenocarcinoma: A case report. World J Clin Cases 2021; 9(6): 1329-1335 [PMID: 33644199 DOI: 10.12998/wjcc.v9.i6.1329] [Cited by in CrossRef: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
7 Lu S, Shih JY, Jang TW, Liam CK, Yu Y. Afatinib as First-Line Treatment in Asian Patients with EGFR Mutation-Positive NSCLC: A Narrative Review of Real-World Evidence. Adv Ther 2021;38:2038-53. [PMID: 33730350 DOI: 10.1007/s12325-021-01696-9] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
8 Kim I, Eom JS, Jo EJ, Mok Ki Uk J, Lee K, Uk Kim K, Park HK, Lee MK, Kim MH. Prognostic value of quantitative measurement of EGFR mutation using peptide nucleic acid clamping in advanced EGFR mutant non-small cell lung cancer patients. Thorac Cancer 2019;10:1561-6. [PMID: 31148357 DOI: 10.1111/1759-7714.13101] [Reference Citation Analysis]